Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INO
Strong SellSinkerInovio Pharmaceuticals, Inc. · Healthcare · United States · $133M · Avg Vol: $7M/d
COMPANY DESCRIPTION
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines for infectious diseases, cancer, and other unmet medical needs using its proprietary CELLECTRA® delivery platform. The company utilizes a unique DNA plasmid technology and electroporation delivery system, aiming to generate robust and durable immune responses for therapeutic and prophylactic purposes. Inovio is a clinical-stage biopharmaceutical company with a broad pipeline, representing a speculative investment based on the success of its novel DNA medicine platform.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.3M | 0.8M | 0.2M | 65.3K | -81.5% | — | 0.7M | 50.6M | 2682.9% |
| EPS | -3.60 | -1.69 | -1.73 | -1.81 | — | -1.03 | -0.73 | -0.44 | — |
| Shares | 82.3M | 82.3M | 82.3M | 69.0M | -16.1% | — | — | — | — |
| Debt | 32.1M | 30.2M | 11.9M | 9.4M | -33.7% | 8.0M | — | — | — |
| Equity | 222.4M | 117.3M | 68.5M | 24.1M | -52.3% | — | — | — | — |
| Op CF | -216.2M | -124.4M | -104.1M | -88.6M | — | -80.6M | — | — | — |
| Inv CF | 109.6M | 87.4M | 104.1M | 14.0M | — | — | — | — | — |
| Fin CF | 81.8M | 5.0M | 51.5M | 53.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INO | Inovio Pharmaceuticals, Inc.(you) | $133M | 3 | Strong Sell |
| CBUS | Cibus, Inc. | $126M | 2 | Strong Sell |
| 2592.HK | Cloudbreak Pharma Inc. | $136M | 1 | Strong Sell |
| HURA | TuHURA Biosciences, Inc. | $134M | 6 | Strong Sell |
| GNLX | Genelux Corporation | $120M | 4 | Strong Sell |
| NTHI | NeOnc Technologies Holdings, Inc. | $122M | 0 | Strong Sell |
| NAUT | Nautilus Biotechnology, Inc. | $113M | 4 | Strong Sell |
| ONCY | Oncolytics Biotech Inc. | $109M | 5 | Strong Sell |
| RANI | Rani Therapeutics Holdings, Inc. | $118M | 7 | Strong Sell |
| HUMA | Humacyte, Inc. | $181M | 2 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%